Chloroaluminium sulphonate phthalocyanine

Drug Profile

Chloroaluminium sulphonate phthalocyanine

Alternative Names: Chloroaluminum sulfonated phthalocyanine

Latest Information Update: 23 Nov 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antineoplastics; Phthalocyanines
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bladder cancer

Most Recent Events

  • 23 Nov 2001 Profile reviewed but no significant changes made
  • 28 Oct 1997 No-Development-Reported for Bladder cancer in Switzerland (Unknown route)
  • 06 Oct 1995 Chloroaluminum sulfonated phthalocyanine is now called chloroaluminium sulphonate phthalocyanine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top